Land: Nederland
Taal: Nederlands
Bron: CBG-MEB (College ter Beoordeling van Geneesmiddelen)
DULOXETINEHYDROCHLORIDE 22,4 mg/stuk SAMENSTELLING overeenkomend met ; DULOXETINE 20 mg/stuk
Sandoz B.V. Veluwezoom 22 1327 AH ALMERE
N06AX21
DULOXETINEHYDROCHLORIDE 22,4 mg/stuk SAMENSTELLING overeenkomend met ; DULOXETINE 20 mg/stuk
Maagsapresistente capsule, hard
AMMONIA (E 527) ; GELATINE (E 441) ; HYPROMELLOSE, Type 2910 (3 - 15 mPa.s) (E 464) ; HYPROMELLOSEFTALAAT ; IJZEROXIDE ZWART (E 172) ; INDIGOKARMIJN (E 132) ; KALIUMHYDROXIDE (E 525) ; MAÏSZETMEEL ; NATRIUMLAURILSULFAAT ; PROPYLEENGLYCOL (E 1520) ; SACCHAROSE ; SCHELLAK (E 904) ; SUIKERMAÏSBOLLETJES ; TALK (E 553 B) ; TITAANDIOXIDE (E 171) ; TRIETHYLCITRAAT (E 1505) ; ZWARTE INKT, AMMONIA (E 527) ; GELATINE (E 441) ; HYPROMELLOSE, Type 2910 (3 - 15 mPa.s) (E 464) ; HYPROMELLOSEFTALAAT ; IJZEROXIDE ZWART (E 172) ; INDIGOKARMIJN (E 132) ; KALIUMHYDROXIDE (E 525) ; MAÏSZETMEEL ; NATRIUMLAURILSULFAAT (E 487) ; PROPYLEENGLYCOL (E 1520) ; SACCHAROSE ; SCHELLAK (E 904) ; SUIKERMAÏSBOLLETJES ; TALK (E 553 B) ; TITAANDIOXIDE (E 171) ; TRIETHYLCITRAAT (E 1505) ; ZWARTE INKT, AMMONIA (E 527) ; GELATINE (E 441) ; HYPROMELLOSE, Type 2910 (3 - 15 mPa.s) (E 464) ; HYPROMELLOSEFTALAAT ; IJZEROXIDE ZWART (E 172) ; INDIGOKARMIJN (E 132) ; KALIUMHYDROXIDE (E 525) ; MAÏSZETMEEL ; NATRIUMLAURILSULFAAT (E 487) ; PROPYLEENGLYCOL (E 1520) ; SACCHAROSE ; SCHELLAK (E 904) ; SUGAR SPHERES ; TALK (E 553 B) ; TITAANDIOXIDE (E 171) ; TRIETHYLCITRAAT (E 1505) ; ZWARTE INKT,
Oraal gebruik
Duloxetine
Hulpstoffen: AMMONIA (E 527); GELATINE (E 441); HYPROMELLOSE, Type 2910 (3 - 15 mPa.s) (E 464); HYPROMELLOSEFTALAAT; IJZEROXIDE ZWART (E 172); INDIGOKARMIJN (E 132); KALIUMHYDROXIDE (E 525); MAÏSZETMEEL; NATRIUMLAURILSULFAAT (E 487); PROPYLEENGLYCOL (E 1520); SACCHAROSE; SCHELLAK (E 904); SUGAR SPHERES; TALK (E 553 B); TITAANDIOXIDE (E 171); TRIETHYLCITRAAT (E 1505); ZWARTE INKT;
1900-01-01
Sandoz B.V. Page 1/9 Duloxetine Sandoz 20 mg / 40 mg, maagsapresistente harde capsules RVG 116085-6 v6 1.3.1.3 Bijsluiter Februari 2021 PACKAGE LEAFLET: INFORMATION FOR THE PATIENT [DULOXETINE SANDOZ 20 MG, MAAGSAPRESISTENTE HARDE CAPSULES DULOXETINE SANDOZ 40 MG, MAAGSAPRESISTENTE HARDE CAPSULES duloxetine _ _ READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any of the side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What [Nationally completed name] is and what it is used for 2. What you need to know before you take [Nationally completed name] 3. How to take [Nationally completed name] 4. Possible side effects 5. How to store [Nationally completed name] 6. Contents of the pack and other information 1. WHAT [NATIONALLY COMPLETED NAME] IS AND WHAT IT IS USED FOR [Nationally completed name] contains the active substance duloxetine. [Nationally completed name] increases the levels of serotonin and noradrenaline in the nervous system. [Nationally completed name] is a medicine to be taken by mouth to treat Stress Urinary Incontinence (SUI) in women. Stress urinary incontinence is a medical condition in which patients have accidental loss or leakage of urine during physical exertion or activities such as laughing, coughing, sneezing, lifting, or exercise. [Nationally completed name] is believed to work by increasing the strength of the muscle that holds back urine when you laugh, sneeze, or perform physical activities. The efficacy of [Nationally completed name] is reinforced when combined with a training program called Pelvic Floor Muscle Training (PFMT). 2. Lees het volledige document
Sandoz B.V. Page 1/19 Duloxetine Sandoz 20 mg/40 mg, maagsapresistente harde capsules RVG 116085-6 1 1311-v7 1.3.1.1 Samenvatting van de Productkenmerken Februari 2021 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Duloxetine Sandoz 20 mg, maagsapresistente harde capsules Duloxetine Sandoz 40 mg, maagsapresistente harde capsules 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each hard gastro-resistant capsule contains 20 mg of duloxetine (as hydrochloride). Excipient with known effect Each hard gastro-resistant capsule contains 34.37 mg of sucrose. Each hard gastro-resistant capsule contains 40 mg of duloxetine (as hydrochloride). Excipient with known effect Each hard gastro-resistant capsule contains 68.74 mg of sucrose. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Hard gastro-resistant capsule. _20 mg hard gastro-resistant capsule _ Opaque blue body, imprinted with ‘163’ and an opaque blue cap, imprinted with ‘A’. Size “4” hard gastro-resistant capsules filled with white to off white colored pellets. _40 mg hard gastro-resistant capsule _ Opaque orange body, imprinted with ‘162’ and an opaque blue cap, imprinted with ‘A’. Size “2” hard gastro-resistant capsules filled with white to off white colored pellets. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS [Nationally completed name] is indicated for women for the treatment of moderate to severe Stress Urinary Incontinence (SUI). [Nationally completed name] is indicated in adults. For further information see section 5.1. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Sandoz B.V. Page 2/19 Duloxetine Sandoz 20 mg/40 mg, maagsapresistente harde capsules RVG 116085-6 1 1311-v7 1.3.1.1 Samenvatting van de Productkenmerken Februari 2021 Posology The recommended dose of [Nationally completed name] is 40 mg twice daily without regard to meals. After 2-4 weeks of treatment, patients should be re-assessed in order to evaluate the benefit and tolerability of the therapy. Some patients may benefit from st Lees het volledige document